1-20 of 28
Tina Nielsen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Identification of High-Risk Population in First-Line Follicular Lymphoma at Screening with a Next Generation Sequencing (NGS) Assay Using Plasma Circulating Tumor DNA (ctDNA): Initial Data from Gallium

Alessia Bottos, Corinna Woestmann, Christopher R. Bolen, Maria Shin, Patrick Bogard, Ehsan Tabari, Andrew S. Davies, Andrea Knapp, Tina Nielsen, Oliver Weigert, Elicia Penuel
Journal: Blood
Blood (2023) 142 (Supplement 1): 1629.
https://doi.org/10.1182/blood-2023-181723
Published: 2023
Journal Articles

Validation of POD24 as a robust early clinical end point of poor survival in FL from 5225 patients on 13 clinical trials

Clinical Trials & Observations
Carla Casulo, Jesse G. Dixon, Jennifer Le-Rademacher, Eva Hoster, Howard S. Hochster, Wolfgang Hiddemann, Robert Marcus, Eva Kimby, Michael Herold, Catherine Sebban, Emmanuel Gyan, Kenneth Foon, Tina Nielsen, Umberto Vitolo, Gilles A. Salles, Qian Shi, Christopher R. Flowers
Journal: Blood
Blood (2022) 139 (11): 1684–1693.
https://doi.org/10.1182/blood.2020010263
Published: 2022
Includes: Supplemental data
Journal Articles

An EZH2 Gene Expression Signature Is Predictive of Differential Efficacy of Chemotherapy Irrespective of EZH2 Mutation Status in Patients with Follicular Lymphoma Treated within the Gallium Trial

Verena Passerini, Vindi Jurinovic, Christopher R Bolen, Andrea Knapp, Alessia Bottos, Julia Richter, Jude Fitzgibbon, Wolfram Klapper, Andrew Davies, Robert Marcus, Michael von Bergwelt, Tina Nielsen, Martin H. Dreyling, Wolfgang Hiddemann, Michael Unterhalt, Eva Hoster, Oliver Weigert
Journal: Blood
Blood (2021) 138 (Supplement 1): 39.
https://doi.org/10.1182/blood-2021-147751
Published: 2021
Journal Articles

Development of a Predictive Model for Cytokine Release Syndrome to Inform Risk Stratification and CRS Management Following Immunotherapy

Krishna V. Komanduri, Anton Belousov, Michelle Byrtek, Antonia Kwan, David Perez-Callejo, Chi-Chung Li, David Carlile, Bruce McCall, Tina Nielsen, Emily C. Piccione
Journal: Blood
Blood (2021) 138 (Supplement 1): 1459.
https://doi.org/10.1182/blood-2021-147303
Published: 2021
Journal Articles

Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma

Clinical Trials & Observations
Christopher R. Bolen, Federico Mattiello, Michael Herold, Wolfgang Hiddemann, Sarah Huet, Wolfram Klapper, Robert Marcus, Farheen Mir, Gilles Salles, Oliver Weigert, Tina Nielsen, Mikkel Z. Oestergaard, Jeffrey M. Venstrom
Journal: Blood
Blood (2021) 137 (19): 2704–2707.
https://doi.org/10.1182/blood.2020008119
Published: 2021
Includes: Supplemental data
Journal Articles

Baseline SUVmax did not predict histological transformation in follicular lymphoma in the phase 3 GALLIUM study

Clinical Trials & Observations Brief Report
Farheen Mir, Sally F. Barrington, Helen Brown, Tina Nielsen, Deniz Sahin, Michel Meignan, Judith Trotman
Journal: Blood
Blood (2020) 135 (15): 1214–1218.
https://doi.org/10.1182/blood.2019001091
Published: 2020
Includes: Supplemental data
Journal Articles

Integration of cell of origin into the clinical CNS International Prognostic Index improves CNS relapse prediction in DLBCL

Clinical Trials & Observations
Magdalena Klanova, Laurie H. Sehn, Isabelle Bence-Bruckler, Federica Cavallo, Jie Jin, Maurizio Martelli, Douglas Stewart, Umberto Vitolo, Francesco Zaja, Qingyuan Zhang, Federico Mattiello, Gila Sellam, Elizabeth A. Punnoose, Edith Szafer-Glusman, Christopher R. Bolen, Mikkel Z. Oestergaard, Guenter R. Fingerle-Rowson, Tina Nielsen, Marek Trneny
Journal: Blood
Blood (2019) 133 (9): 919–926.
https://doi.org/10.1182/blood-2018-07-862862
Published: 2019
Includes: Supplemental data
Journal Articles

Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy

Clinical Trials & Observations
Shigeru Kusumoto, Luca Arcaini, Xiaonan Hong, Jie Jin, Won Seog Kim, Yok Lam Kwong, Marion G. Peters, Yasuhito Tanaka, Andrew D. Zelenetz, Hiroshi Kuriki, Günter Fingerle-Rowson, Tina Nielsen, Eisuke Ueda, Hanna Piper-Lepoutre, Gila Sellam, Kensei Tobinai
Journal: Blood
Blood (2019) 133 (2): 137–146.
https://doi.org/10.1182/blood-2018-04-848044
Published: 2019
Includes: Supplemental data
Journal Articles

Tocilizumab to Prevent Infusion-Related Events in Patients with Chronic Lymphocytic Leukemia and Co-Morbidities Treated with Obinutuzumab and Chlorambucil: Results from the Randomized Phase Ib GALACTA Trial

Ciara Louise Freeman, MRCP, MSc, FRCPath, MBBChir, Sebastian Böttcher, Javier De la Serna, Julio Delgado, Franca Falzetti, Marco Gobbi, MD, Sandra Lejniece, Maria Chiara Di Bernardo, Navita L Mallalieu, Tina Nielsen, Andrea Knapp, John G. Gribben
Journal: Blood
Blood (2018) 132 (Supplement 1): 4419.
https://doi.org/10.1182/blood-2018-99-118238
Published: 2018
Journal Articles

Baseline Suvmax Did Not Predict Histological Transformation from Follicular Lymphoma to Aggressive Lymphoma in the Phase III GALLIUM Study

Farheen Mir, MBBS, Sally F Barrington, Michel Meignan, Helen Brown, Tina Nielsen, Deniz Sahin, Judith Trotman
Journal: Blood
Blood (2018) 132 (Supplement 1): 4160.
https://doi.org/10.1182/blood-2018-99-116686
Published: 2018
Journal Articles

Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials

Sarah C. Rutherford, Michael Herold, Wolfgang Hiddemann, Lale Kostakoglu, Robert Marcus, Maurizio Martelli, Laurie H Sehn, MDMPH, Marek Trněný, Judith Trotman, Umberto Vitolo, Tina Nielsen, Federico Mattiello, Deniz Sahin, Gila Sellam, Peter Martin, FRCPC, MD MS
Journal: Blood
Blood (2018) 132 (Supplement 1): 1605.
https://doi.org/10.1182/blood-2018-99-114913
Published: 2018
Journal Articles

Atezolizumab in Combination with Obinutuzumab and Lenalidomide Demonstrates Favorable Activity and Manageable Toxicity in Patients with Relapsed/Refractory Follicular Lymphoma (FL): An Interim Analysis of a Phase Ib/II Trial

Gilles Salles, MD PhD, Nilanjan Ghosh, MD PhD, Izidore S. Lossos, MD, Maria Lia Palomba, MD, Amitkumar Mehta, MD, Olivier Casasnovas, Don Stevens, MD, Ana Abajo, Tina Nielsen, Surya Chitra, Michael Wenger, Franck Morschhauser
Journal: Blood
Blood (2018) 132 (Supplement 1): 1603.
https://doi.org/10.1182/blood-2018-99-114992
Published: 2018
Journal Articles

No Added Benefit of Eight Versus Six Cycles of CHOP When Combined with Rituximab in Previously Untreated Diffuse Large B-Cell Lymphoma Patients: Results from the International Phase III GOYA Study

Laurie H Sehn, MDMPH, Angela Giovanna Congiu, Dominic J. Culligan, Mercedes Gironella, Dok Hyun Yoon, Michinori Ogura, Andras Rosta, Jun Zhu, Aino Launonen, Tina Nielsen, Gila Sellam, Marek Trněný, Umberto Vitolo, Maurizio Martelli
Journal: Blood
Blood (2018) 132 (Supplement 1): 783.
https://doi.org/10.1182/blood-2018-99-116845
Published: 2018
Journal Articles

Minimal Residual Disease Response at End of Induction and during Maintenance Correlates with Updated Outcome in the Phase III GALLIUM Study of Obinutuzumab- or Rituximab-Based Immunochemotherapy in Previously Untreated Follicular Lymphoma Patients

Christiane Pott, Eva Hoster, Britta Kehden, Michael Unterhalt, Michael Herold, Richard van der Jagt, Ann Janssens, Michael Kneba, Jiri Mayer, MD, Christopher Pocock, MD PhD, Andrea Knapp, Nathalie Danesi, Tina Nielsen, Helen Brown, Kirsten Mundt, Robert Marcus, Wolfgang Hiddemann
Journal: Blood
Blood (2018) 132 (Supplement 1): 396.
https://doi.org/10.1182/blood-2018-99-115930
Published: 2018
Journal Articles

Safety and Efficacy of Atezolizumab in Combination with Rituximab Plus CHOP in Previously Untreated Patients with Diffuse Large B-Cell Lymphoma (DLBCL): Primary Analysis of a Phase I/II Study

Anas Younes, MD, John M Burke, Bruce Cheson, MD, Catherine Diefenbach, MD, Silvia Ferrari, Uwe Hahn, Eliza Hawkes, Cyrus Khan, Izidore S. Lossos, MD, Gerardo Musuraka, Monica Tani, Umberto Vitolo, Sam Yuen, Mikkel Z Oestergaard, Surya Chitra, Michael Wenger, Tina Nielsen, Gila Sellam, Jeff Sharman, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2969.
https://doi.org/10.1182/blood-2018-99-116678
Published: 2018
Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Did Not Predict Outcomes in Follicular Lymphoma Patients Treated with First-Line Immunochemotherapy and Antibody Maintenance in the Phase III GALLIUM Study

Sally F Barrington, Judith Trotman, Deniz Sahin, David Belada, Andrew Davies, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Wolfgang Hiddemann, Robert Marcus, Tina Nielsen, Federico Mattiello, Harald Zeuner, Michel Meignan
Journal: Blood
Blood (2018) 132 (Supplement 1): 2882.
https://doi.org/10.1182/blood-2018-99-117235
Published: 2018
Journal Articles

A Novel Prognostic Model That Is Superior to FLIPI-1 and FLIPI-2 and Integrates Clinical and Treatment Factors to Predict Progression-Free Survival and Early Treatment Failure in Patients with Follicular Lymphoma in the GALLIUM Trial

Farheen Mir, MBBS, Andrew Grigg, Michael Herold, Wolfgang Hiddemann, Robert Marcus, John F. Seymour, MBBS, PhD, Christopher R Bolen, Andrea Knapp, Aino Launonen, Federico Mattiello, Tina Nielsen, Mikkel Z Oestergaard, Michael Wenger, Carla Casulo, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2872.
https://doi.org/10.1182/blood-2018-99-114620
Published: 2018
Journal Articles

Validation of POD24 As a Robust Early Clinical Endpoint of Poor Survival in Follicular Lymphoma: Results from the Follicular Lymphoma Analysis of Surrogacy Hypothesis (FLASH) Investigation Using Individual Data from 5,453 Patients on 13 Clinical Trials

Carla Casulo, MD, Jennifer Le-Rademacher, PhD, Jesse Dixon, Stat, Gilles Salles, MD, Eva Hoster, Michael Herold, MD, Wolfgang Hiddemann, Catherine Sebban, MD, Robert Marcus, Eva Kimby, Howard Hochster, MD, Umberto Vitolo, MD, Emmanuel Gyan, MDPhD, Fang-Shu Ou, PhD, Tina Nielsen, Kenneth A. Foon, MD, Shi Qiuan, PhD, Christopher Flowers, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 412.
https://doi.org/10.1182/blood.V130.Suppl_1.412.412
Published: 2017
Journal Articles

Low Peripheral Blood NK Cell Count Is Associated with Worse Clinical Outcome in Patients with Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Immunochemotherapy: Results from the Frontline Phase 3 GALLIUM and GOYA Trials

Magdalena Klanova, MD, Mikkel Z. Oestergaard, Marek Trněný, MD PhD, Wolfgang Hiddemann, MD PhD, Robert Marcus, Laurie H. Sehn, MDMPH, Umberto Vitolo, MD, Alexandra Bazeos, Valentin Goede, MD, Harald Zeuner, Andrea Knapp, Denis Sahin, Nathalie Danesi, Christopher Bolen, Susan Robson, Jeffrey M. Venstrom, Tina Nielsen, Günter Fingerle-Rowson
Journal: Blood
Blood (2017) 130 (Supplement 1): 727.
https://doi.org/10.1182/blood.V130.Suppl_1.727.727
Published: 2017
Journal Articles

Baseline PET-Derived Metabolic Tumor Volume Metrics Predict Progression-Free and Overall Survival in DLBCL after First-Line Treatment: Results from the Phase 3 GOYA Study

Lale Kostakoglu, Maurizio Martelli, Laurie H. Sehn, MDMPH, David Belada, Angelo-Michele Carella, Neil Chua, Eva Gonzalez-Barca, Xiaonan Hong, Antonio Pinto, MD, Yuankai Shi, Yoichi Tatsumi, Günter Fingerle-Rowson, Andrea Knapp, Federico Mattiello, Tina Nielsen, Gila Sellam, Denis Sahin, Umberto Vitolo, MD, Marek Trněný, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 824.
https://doi.org/10.1182/blood.V130.Suppl_1.824.824
Published: 2017